Research Funding & Grant Resources

Current Research Fundings

Emaad Abdel-Rahman, MBBS

CV185-450 - RENal hemodialysis patients Allocated apixaban versus warfarin in Atrial Fibrillatio (RENAL-AF)04/10/18 - 04/09/21
17530-14248 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, eventdriven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects05/02/18 - 05/01/21
16244-14248 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, eventdriven Phase III study to investigate the efficacy and safety of finerenone / Bayer Study 1624405/02/18 - 05/01/21
Safety and Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis4/23/14 - 9/18/19

Brendan Bowman, MD

Center for Innovative Technology - Optimizing Anemia Dosing Algorithms by Leveraging EMR Data to Improve Outcomes in End Stage Renal Disease7/1/18 - 3/31/20

Michael G. Brown, PhD

NIH/NAIAD 5R01AI050072-17 - Molecular study mouse virus resistance mechanisms2/22/17 – 1/31/22
NIH/NAIAD 1R21AI141943-01A1 - TNFRSF Genetics Related to NK Cell Control of MCMV6/1/19 – 5/31/21

Tushar Chopra, MD

ASN – Bennett Clinical Scholars - PD curriculum development to improve PD prescriptions writing7/1/19 – 6/30/21

Alden Doyle, MD

SN-C-0010 CareDX - Evaluation of patient outcomes from the Kidney allograft outcomes allosure registry (KOAR) agreement04/23/18 - 06/01/21

Uta Erdbruegger, MD

NIH/NHLBI 5K23HL126101-05 - Circulating and urinary microparticles as markers of end-organ damage in hypertension7/20/15 – 4/30/20
American Heart Association - Fellowship (Sabrina La Salvia) Subtypes of Leukocytes derived Extracellular Vesicles in Hypertension7/1/18 – 6/30/20

Shuman Fu, MD

NIH 5R01AR047988-18 - Cellular and Genetic Basis of Systemic Lupus 4/22/16 – 3/31/21
Lupus Research Alliance - Local Factors Contributing to Pathogenesis of Proliferative Lupus Nephritis
1/1/17 – 9/30/20
NIH/NIAID 5R01AI139673-02 - Infections, Microbiome and HLA-DR in the Induction of Lupus Related Auto-antibodies8/10/18 – 7/31/23

Kambiz Kalantari, MD

ST-001-CALISTA - Hope Pharma: Calciphylaxis Study04/27/18-04/26/21

Sana Khan, MD

Arbor Research Collaborative for Health - The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)1/14/19 – 1/13/22

Peter Lobo, MD

R01DK114366-01A1 - CpG and B cells, pretreated ex-vivo with natural IgM, protect against renal IRI05/02/18 – 03/31/22

Mark D. Okusa, MD

NIH/NIDDK 1R01DK123248-01 - Neuroimmune Regulation of Acute Kidney Injury09/19/2019 – 07/31/2024
5 T32 DK072922 - Kidney Disease and Inflammation08/01/06 - 08/31/21
NIH/NIDDK 5R01DK085259-08 - Sphingolipids in Acute Kidney Injury and Disease Progression7/1/15 – 6/30/20
NIHI/NIDDK 5R01DK105133-05 - Ultrasound for Non-Invasive Prevention of Acute Kidney Injury9/21/15 – 7/31/20
NIH/NIDDK R25DK123248-01 - The University of Virginia Kidney Technology Development Research Education Program04/01/20– 1/30/25
ASN – Ben Lipps Fellowship - Nabin Poudel Fellowship – Pannexin 1 And Acute Kidney Injury7/1/19 – 6/30/21

Mitchell Rosner, MD

Otsuka Phrmaceutical Development and Comercialization - Otsuka Tolvaptan Polycystic Kidney Disease (OPC-41061)9/1/14 – 1/31/20
Kadmon Corporation, LLC KD019-211 - A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects with Autosomal Dominant Polycystic Kidney Disease12/1/17 – 11/30/20
Kadmon Corporation, LLC KD019-ext - Protocol KD019-101 Extension 1/4/16 – 11/30/20

Julia Scialla, MD

NIH/NIDDK R01 DK111952 - Integrated Mineral Metabolism Treatment Strategies in Patients on Dialysis7/1/19 – 2/28/21

Rahul Sharma, PhD

NIH/NIDDK 5R01DK104963-04 - Regulatory T Cells in Acute Kidney Injury12/15/15 – 11/30/20
NIH/Wake Forrest University - The TREX1 Pathway in Autoimmune Disease1/1/16 – 12/31/19
NIH/NIDDK 5R01DK105833-04 - Targeting Treg for Therapy of Lupus Glomerulonephritis
3/1/16 – 2/29/20

Sundararaman Swaminathan, MD

NIH/NIDDK 5R01DK103043-04 - Targeting Cellular Iron Dnamics for Protection in Kidney Injury7/13/15 – 6/30/20
Grant Resources

The Grants and Contracts Administrator requires a minimum of 30 days notice in advance of the sponsor’s grant deadline.

General Resources